Showing 5271-5280 of 10504 results for "".
- GPX4 Modulator Shows Early Promise in First-in-Human Studyhttps://practicaldermatology.com/news/gpx4-modulator-shows-early-promise-in-first-in-human-study/2486474/A novel topical therapy targeting cellular senescence showed early biologic activity across multiple dermatologic conditions in a Phase 1 clinical trial, according to data presented by Frederick Beddingfield III, MD, PhD, FAAD, at the Dermatology Innovation Forum during the American Academy of De
- Lebrikizumab Shows Durable Efficacy Through 4 Years in Atopic Dermatitishttps://practicaldermatology.com/news/lebrikizumab-shows-durable-efficacy-through-4-years-in-atopic-dermatitis/2486468/Long-term data from the Phase 3b ADlong study show that lebrikizumab provides sustained skin clearance and itch relief for up to four years in patients with moderate-to-severe atopic dermatitis (AD), according to findings presented at the American Academy of Dermatology (AAD) 2026 Annual Meeting.
- Nemolizumab Shows Efficacy in Pediatric Atopic Dermatitishttps://practicaldermatology.com/news/nemolizumab-shows-efficacy-in-pediatric-atopic-dermatitis/2486457/Nemolizumab, an IL-31 receptor alpha (IL-31Rα) antagonist, demonstrated favorable pharmacokinetics, sustained efficacy, and a consistent safety profile in children aged 2 to 11 years with moderate-to-severe atopic dermatitis (AD), according to Phase 2 data presented by Linda Stein Gold, MD, at th
- Upadacitinib Shows Strong Hair Regrowth in Alopecia Areatahttps://practicaldermatology.com/news/upadacitinib-shows-strong-hair-regrowth-in-alopecia-areata/2486456/Upadacitinib demonstrated robust efficacy in both adolescents and adults with severe alopecia areata (AA), with particularly strong responses observed in younger patients, according to a subgroup analysis of two Phase 3 trials presented by Melinda Gooderham, MD, MSc, at the American Academy of De
- IL-15 Blockade Plus Phototherapy Shows Promise in Vitiligohttps://practicaldermatology.com/news/il-15-blockade-plus-phototherapy-shows-promise-in-vitiligo/2486454/Targeting IL-15 with ordesekimab in combination with narrowband ultraviolet B (nbUVB) phototherapy led to greater repigmentation in patients with non-segmental vitiligo, according to results from a randomized, placebo-controlled trial presented by Brett King, MD, PhD, at the American Academy of D
- Dersimelagon Improves Sunlight Tolerance in EPP and XLPhttps://practicaldermatology.com/news/dersimelagon-improves-sunlight-tolerance-in-epp-and-xlp/2486452/Dersimelagon, an oral melanocortin 1 receptor (MC1R) agonist, significantly improved sunlight tolerance in patients with erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), according to Phase 3 INSPIRE trial results presented by Amy Dickey Yeung, MD, at the American Academy of
- Molecular Profiling Reveals Personalized Pathways in Skin Aginghttps://practicaldermatology.com/news/molecular-profiling-reveals-personalized-pathways-in-skin-aging/2486451/A translational biomarker study presented at the American Academy of Dermatology (AAD) 2026 Annual Meeting highlighted distinct molecular signatu
- Roflumilast Cream Shows Safety and Efficacy in Infants With Atopic Dermatitishttps://practicaldermatology.com/news/roflumilast-cream-shows-safety-and-efficacy-in-infants-with-atopic-dermatitis/2486449/Roflumilast cream 0.05%, a topical phosphodiesterase 4 (PDE4) inhibitor, demonstrated favorable safety and clinically meaningful efficacy in infants with atopic dermatitis (AD), according to results from the Phase 2 INTEGUMENT-INFANT study presented by Lawrence F. Eichenfield, MD, at the American
- Transcriptomic Study Identifies IL-1β Axis in Hidradenitis Suppurativahttps://practicaldermatology.com/news/transcriptomic-study-identifies-il-1b-axis-in-hidradenitis-suppurativa/2486448/Comprehensive transcriptomic profiling of hidradenitis suppurativa (HS) highlights a dominant macrophage-derived IL-1β/NLRP3 inflammasome axis, p
- Long-term Upadacitinib Data Show Low Rates of MACE, Malignancyhttps://practicaldermatology.com/news/low-rates-of-mace-malignancy-observed-with-upadacitinib-over-6-years/2486427/Long-term safety data from three phase 3 trials (Measure Up 1, Measure Up 2, and AD Up) provided a 6-year view of upadacitinib in moderate-to-severe atopic dermatitis (AD) stratified across multiple age groups. A total of 2,68